TJ you are absolutely correct! In my opinion totally undervalued and I wonder who in their right mind would be selling the 100k+ parcels at these prices. Every now and then a large parcel is snapped up without lifting the price. Accumulation by some? What would I know? That is a sore point. I don't know. Also a little more information from management about the trials would be helpful. Here is a bit of news to brighten up the day for fellow longs who haven't done the research. Glaxo Smith Kline have just had on 18.12.2013 a COPD drug approval issued by the FDA. See link: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm379057.htm If you check out the box label warning you quickly realise you would have to be very ill indeed to take this drug. It would seem then that if the FDA is approving this drug then there must be a large unmet need for effective COPD drugs with low side effects. Makes Nadalol look good. GSK used over 2400 subjects in the trial for their drug. Raises the question why can't IVX find 136 subjects for a smoking trial - ( they are still recruiting ) Awaiting news, Best wishes for the New Year - Chairs
IVX Price at posting:
8.9¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)